Rhonda Collins

Chief Nursing Officer at Vocera Communications, Inc.

Rhonda Collins

Rhonda Collins

Chief Nursing Officer at Vocera Communications, Inc.

Overview
RelSci Relationships

659

Relationships
RelSci Relationships are individuals Rhonda Collins likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chairman of the Board, President & Chief Executive Officer at Vocera Communications, Inc.

Relationship likelihood: Strong

Chief Medical Officer at Vocera Communications, Inc.

Relationship likelihood: Strong

Former President-Dietary Products at Kraft General Foods Corp.

Relationship likelihood: Strong

Vice President-Business & Corporate Development at Vocera Communications, Inc.

Relationship likelihood: Strong

Vice President of Professional Services at Vocera Communications, Inc.

Relationship likelihood: Strong

Founder at Vocera Communications, Inc.

Relationship likelihood: Strong

Chief Financial Officer at Vocera Communications, Inc.

Relationship likelihood: Strong

Secretary, General Counsel & Vice President-Legal at Vocera Communications, Inc.

Relationship likelihood: Strong

Chief Marketing Officer at Vocera Communications, Inc.

Relationship likelihood: Strong

Chief Technology Officer at Vocera Communications, Inc.

Relationship likelihood: Strong

Paths to Rhonda Collins
Potential Connections via
Relationship Science
You
Rhonda Collins
Chief Nursing Officer at Vocera Communications, Inc.
Education

The University of Texas at Arlington is a growing research powerhouse committed to life-enhancing discovery, innovative instruction, and caring community engagement. An educational leader in the heart of the thriving North Texas region, UT Arlington nurtures minds within an environment that values excellence, ingenuity, and diversity. Guided by world-class faculty members, the University’s 33,300 students represent 120 countries and pursue more than 180 bachelor’s, master’s, and doctoral degrees in a broad range of disciplines. UT Arlington is dedicated to producing the lifelong learners and critical thinkers our region and nation demand. More than 107,000 of the University’s 169,000 alumni live in North Texas and contribute to our annual economic impact of $12.8 billion in the region. With a growing number of campus residents, UT Arlington has become a first-choice university for students seeking a vibrant college experience. In addition to receiving a first-rate education, our students participate in a robust slate of co-curricular activities that prepare them to become the next generation of leaders.

Career History
Chief Nursing Officer
2014 - Current

Vocera is a leading provider of mobile communication solutions focused on addressing the most critical communication challenges facing hospitals today. We help our customers improve patient safety and satisfaction, and increase hospital efficiency and productivity with our Voice Communication solution and new Secure Messaging and Care Transition solutions. The Joint Commission data base on sentinel events identifies communication issues as one of the root causes in 82% of the reported occurrences in 2010. Additionally, a study published in the Journal of Healthcare Management conducted by Agarwal et. al.,"Quantifying the Economic Impact of Communication Inefficiencies in U.S. Hospitals" found that inefficient communication costs U.S. hospitals more than $12 billion annually or better than $4 million for a 500-bed hospital. More than 800 hospitals and healthcare facilities leverage Vocera solutions to achieve improved clinical, operational, and financial outcomes. The Vocera Voice Communication solution and the Vocera Care Transition solution are exclusively endorsed by the American Hospital Association.

Vice President & General Manager
Prior

Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients. Its product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for whole blood and blood components collection and processing as well as for transfusion medicine and cell therapies.

Vice President
Prior

Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. A key medical technology innovator, Masimo is responsible for the invention of award-winning noninvasive technologies that are revolutionizing patient monitoring, including Masimo SET® pulse oximetry, Masimo rainbow® SET Pulse CO-Oximetry and new Masimo noninvasive and continuous total hemoglobin (SpHb®) monitoring technology. These new rainbow® technologies are expected to open new markets and significantly expand the company’s growth opportunities. Joe Kiani founded Masimo in 1989 as a private "garage start-up" company because he was convinced that the use of adaptive signal processing in the measurement of physiological parameters could solve the problems of low perfusion and motion, which had long plagued in-vivo monitoring and especially pulse oximetry. Today, Masimo has grown into a successful publicly traded medical technology company employing over 2,500 people worldwide with product revenues that have increased 4-fold in the last five years. In addition, the company has technology license and OEM agreements with leading patient monitoring manufacturers spanning the globe including Atom, Datascope, GE Medical, Medtronic, Philips, Spacelabs, and Zoll. Masimo is not only the inventor of Measure-through Motion and Low Perfusion pulse oximetry and Pulse CO-Oximetry technologies, but is also the market-leading pulse oximetry technology solution. In 1995, Masimo debuted Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo SET—a breakthrough in pulse oximetry technology that virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events. More than 100 independent and objective studies demonstrate that Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow® SET Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring platform that measures many blood constituents that previously required invasive procedures. Masimo rainbow SET continuously and noninvasively measures total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®) and pleth variability index (PVI®), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), enabling early detection and treatment of potentially life-threatening conditions. For more than 20 years now, Masimo has been focused on a singular mission—to create noninvasive patient monitoring technologies that are more effective and reliable and to improve patient outcomes and reduce the cost of care by bringing these technologies to new sites and applications. The result is a portfolio of clinically-proven products that lead the way in innovation, performance and patient safety by giving health care providers the information they need to optimize clinical decision-making

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Rhonda Collins. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Rhonda Collins's profile does not indicate a business or promotional relationship of any kind between RelSci and Rhonda Collins.